These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 24520851)

  • 1. No benefit of saxagliptin on cardiovascular outcomes in type 2 diabetes mellitus: potential explanations.
    Jialal I; Dhindsa S
    Metab Syndr Relat Disord; 2014 Apr; 12(3):157-8. PubMed ID: 24520851
    [No Abstract]   [Full Text] [Related]  

  • 2. Saxagliptin and tuberculosis.
    Prescrire Int; 2013 Jan; 22(134):17. PubMed ID: 23383408
    [No Abstract]   [Full Text] [Related]  

  • 3. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
    Mosenzon O; Raz I; Scirica BM; Hirshberg B; Stahre CI; Steg PG; Davidson J; Ohman P; Price DL; Frederich B; Udell JA; Braunwald E; Bhatt DL
    Diabetes Metab Res Rev; 2013 Jul; 29(5):417-26. PubMed ID: 23564755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons from SAVOR and EXAMINE: some important answers, but many open questions.
    Schernthaner G; Sattar N
    J Diabetes Complications; 2014; 28(4):430-3. PubMed ID: 24713467
    [No Abstract]   [Full Text] [Related]  

  • 5. Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.
    Borja-Hart NL; Whalen KL
    Ann Pharmacother; 2010 Jun; 44(6):1046-53. PubMed ID: 20460554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saxagliptin demonstrates no increased risk for cardiovascular death, heart attack or stroke in the SAVOR cardiovascular outcomes trial.
    Hardy G
    Cardiovasc J Afr; 2013 Aug; 24(7):290. PubMed ID: 24217308
    [No Abstract]   [Full Text] [Related]  

  • 7. Saxagliptin + metformin. Mostly disadvantages.
    Prescrire Int; 2013 Feb; 22(135):40. PubMed ID: 23444500
    [No Abstract]   [Full Text] [Related]  

  • 8. Saxagliptin (Onglyza) for type 2 diabetes.
    Med Lett Drugs Ther; 2009 Nov; 51(1324):85-6. PubMed ID: 19890244
    [No Abstract]   [Full Text] [Related]  

  • 9. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saxagliptin efficacy.
    Valiquette G
    Diabetes Obes Metab; 2010 Aug; 12(8):734; author reply 735. PubMed ID: 20590752
    [No Abstract]   [Full Text] [Related]  

  • 11. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
    Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Frederich R; Wiviott SD; Hoffman EB; Cavender MA; Udell JA; Desai NR; Mosenzon O; McGuire DK; Ray KK; Leiter LA; Raz I;
    N Engl J Med; 2013 Oct; 369(14):1317-26. PubMed ID: 23992601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.
    Schwartz SL
    Ann Med; 2012 Mar; 44(2):157-69. PubMed ID: 22132773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):383-94. PubMed ID: 22313172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline differences in the SAVOR trial.
    Luijendijk HJ; Hulshof TA
    Diabetes Obes Metab; 2015 Dec; 17(12):1202. PubMed ID: 26094750
    [No Abstract]   [Full Text] [Related]  

  • 15. Exploration of the DPP-4 inhibitors with a focus on saxagliptin.
    Shubrook JH; Colucci RA; Schwartz FL
    Expert Opin Pharmacother; 2009 Dec; 10(17):2927-34. PubMed ID: 19929711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.
    Cook W; Bryzinski B; Slater J; Frederich R; Allen E
    Postgrad Med; 2013 May; 125(3):145-54. PubMed ID: 23748515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saxagliptin in type 2 diabetes.
    Billiones R
    Drugs Today (Barc); 2010 Feb; 46(2):101-8. PubMed ID: 20393638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saxagliptin for the treatment of diabetes - a focus on safety.
    Cernea S; Cahn A; Raz I
    Expert Opin Drug Saf; 2016 May; 15(5):697-707. PubMed ID: 26923222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
    Gallwitz B
    Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
    [No Abstract]   [Full Text] [Related]  

  • 20. Dipeptidyl peptidase-4 inhibitors and cardiovascular safety.
    Davis TM
    Med J Aust; 2014 May; 200(8):450-1. PubMed ID: 24794596
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.